Markets:

Overview

News

Currencies

International

Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

33.87 -0.87 (-2.50%)

Streaming Delayed Price Updated: 11:00 AM EDT, Aug 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Should Eli Lilly Investors Be Worried About a Threat From Amylyx? ↗

August 30, 2026

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

Via The Motley Fool

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week ↗

August 21, 2026

The biotech delivered excellent news from the laboratory.

Via The Motley Fool

Why Amylyx Pharmaceuticals Stock Skyrocketed Today ↗

August 18, 2026

GLP-1 drugs aren't just for weight loss.

Via The Motley Fool

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 18, 2026

Gainers AIxCrypto Hldgs (NASDAQ:AIXC) stock increased by 132.0% to $1.65 during Tuesday's regular session. The market value of their outstanding shares is at $14.3 million. Amylyx Pharmaceuticals...

Via Benzinga

Amylyx Pharmaceuticals (NASDAQ:AMLX) Misses on Q2 Bottom Line as LUCIDITY Readout Looms ↗

August 06, 2026

Via Chartmill

Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 Loss Slightly Wider Than Expected as All Eyes Turn to Q3 Avexitide Trial Data ↗

May 07, 2026

Via Chartmill

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Narrower-Than-Expected Q4 Loss, Focus Remains on Key 2026 Data ↗

March 03, 2026

Via Chartmill

Amylyx Phase III Avexitide Trial Cuts Severe Hypoglycemic Events 55% ↗

August 18, 2026

Amylyx Pharmaceuticals (NASDAQ:AMLX) said its Phase III LUCIDITY trial of avexitide met its primary endpoint, reducing the composite rate of clinically significant hypoglycemic events by 55% versus...

Via MarketBeat

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 18, 2026

Gainers Amylyx Pharmaceuticals (NASDAQ:AMLX) stock increased by 27.5% to $27.32 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.3 billion. bioAffinity...

Via Benzinga

Amylyx (AMLX) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

LUCIDITY data readout expected late August or early September.

Via The Motley Fool

Topics Earnings

Amylyx Pharmaceuticals Q2 Earnings Call Highlights ↗

August 06, 2026

Amylyx Pharmaceuticals (NASDAQ:AMLX) said its pivotal Phase III LUCIDITY trial of avexitide in post-bariatric hypoglycemia, or PBH, has completed final patient visits, with top-line data expected in...

Via MarketBeat

Topics Earnings

Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape ↗

June 10, 2026

Amylyx Pharmaceuticals (NASDAQ:AMLX) Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia,...

Via MarketBeat

What to Know About This Fund's $10 Million Bet on Gold Miners ↗

May 24, 2026

ASA Gold and Precious Metals Limited targets global mining equities, specializing in gold, silver, and other precious minerals investments.

Via The Motley Fool

Topics Economy

Amylyx Stock: Why the Full Pipeline Story Matters ↗

May 24, 2026

Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares

Via MarketBeat

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗

May 19, 2026

This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.

Via The Motley Fool

Topics Regulatory Compliance

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗

May 19, 2026

Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.

Via The Motley Fool

Topics Regulatory Compliance

Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus ↗

May 14, 2026

Amylyx Pharmaceuticals (NASDAQ:AMLX) is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric hypoglycemia, or PBH, with data from the LUCIDITY trial expected in the...

Via MarketBeat

Amylyx (AMLX) Q1 2026 Earnings Transcript ↗

May 08, 2026

Amylyx (AMLX) Q1 2026 Earnings Transcript

Via The Motley Fool

Amylyx (AMLX) Q4 2025 Earnings Call Transcript ↗

March 03, 2026

Amylyx (AMLX) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗

February 25, 2026

This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗

February 25, 2026

RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials.

Via The Motley Fool

Topics Regulatory Compliance

Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗

February 25, 2026

This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology.

Via The Motley Fool

Topics Regulatory Compliance

Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million ↗

February 01, 2026

A Co-CEO of a leading neurotherapeutics developer reported significant insider selling amid a year of standout stock performance. But the sale is not what it seems.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗

December 09, 2025

A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.

Via The Motley Fool

Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗

December 09, 2025

Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down.

Via The Motley Fool

Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗

December 09, 2025

A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story.

Via The Motley Fool

Topics Regulatory Compliance

With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗

December 03, 2025

One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗

November 17, 2025

A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗

November 17, 2025

This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.

Via The Motley Fool

Topics Regulatory Compliance

Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗

November 17, 2025

A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.

Via The Motley Fool

Topics Regulatory Compliance

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.